Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL366796 | 0.98 | MAPK1 (0.57) | MAPK1LOXL2KDM4EL3MBTL1MAPT | |
| Hydrochloric Acid SCHEMBL6878590 | 0.98 | MAPK1 (0.57) | MAPK1LOXL2KDM4EL3MBTL1MAPT | |
| Trifluoroacetic Acid SCHEMBL2086389 | 0.90 | MAPK1 (0.50) | MAPK1LOXL2KDM4EL3MBTL1MAPT | |
| SCHEMBL6205940 | 0.87 | MAPK1 (0.56) | MAPK1LOXL2KDM4EL3MBTL1MAPT | |
| SCHEMBL29695095 | 0.84 | MAPK1 (0.61) | MAPK1LOXL2KDM4EL3MBTL1MAPT | |
| SCHEMBL204895 | 0.84 | MAPK1 (0.61) | MAPK1LOXL2KDM4EL3MBTL1MAPT | |
| SCHEMBL1441132 | 0.84 | MAPK1 (0.61) | MAPK1LOXL2KDM4EL3MBTL1MAPT | |
| SCHEMBL7930158 | 0.83 | LMNA (0.53) | KDM4EL3MBTL1MAPTALDH1A1CA1 | |
| SCHEMBL9446828 | 0.83 | MAPK1 (0.51) | MAPK1LOXL2KDM4EL3MBTL1MAPT | |
| SCHEMBL17298235 | 0.83 | MAPK1 (0.59) | MAPK1LOXL2KDM4EL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| EP-4584263-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND USES THEREOF | Chong Kun Dang Pharmaceutical Corp. (KR) | 2025-07-16 | — | — | EP | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118239926-A | TLR7 and 8 inhibitors, preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024054071-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND USES THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-03-14 | — | — | WO | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| US-11535614-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2022-12-27 | — | — | US | disclosed |
| CN-113563245-A | Substituted pyrrolidine compounds and application thereof in medicines | 广东东阳光药业有限公司 | 2021-10-29 | — | — | CN | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| EP-1615636-A1 | BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC | 2005-09-29 | — | — | US | disclosed |
| US-6858613-B2 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC. (US) | 2005-02-22 | — | — | US | disclosed |
| WO-2004089366-A1 | BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER JAPAN, INC. (JP) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204409-A1 | Bicyclic compounds as NR2B receptor antagonists | ANDO KAZUO (JP) | 2004-10-14 | — | — | US | disclosed |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| US-5547961-A | USING TETRAHYDROIMIDAZOPYRIDINE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1996-08-20 | — | — | US | disclosed |
| US-5336679-A | Treatment of irritable bowel syndrome | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1994-08-09 | — | — | US | disclosed |
| EP-0532754-A1 | TETRAHYDROIMIDAZOPYRIDINE DERIVATIVE OR ITS SALT | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | NAT1, CYP11B1, COASY | MAPK1 2806/4885LOXL2 4391/4885KDM4E 3522/4885 |
| US-20040204409-A1 | Bicyclic compounds as NR2B receptor antagonists | GRIN1, GRIN2B, GRIN2A | MAPK1 1578/4885LOXL2 2258/4885KDM4E 2434/4885 |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC3 | MAPK1 2358/4885LOXL2 3851/4885KDM4E 544/4885 |
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | CHRNA7, UGT2B7, CHRNA5 | MAPK1 3786/4885LOXL2 4516/4885KDM4E 2428/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | MAPK1 3535/4885LOXL2 3135/4885KDM4E 1088/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | MAPK1 72/4885LOXL2 1286/4885KDM4E 1665/4885 |
| US-11535614-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | MAPK1 1176/4885LOXL2 4083/4885KDM4E 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.